Ernexa Therapeutics Inc. Stock Split Ratio
Ernexa Therapeutics Inc. (ERNA) had Stock Split Ratio of 5.00% as of 2022-09-21, per its 10-K filed 2023-03-20.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2023-03-20
- Ernexa Therapeutics Inc. stockholders' equity note, stock split, conversion ratio for the quarter ending 2021-03-31 was 50.00%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio 3 month |
|---|---|---|
| 2022-09-21 | 5.00% 10-K · filed 2023-03-20 | |
| 2021-03-31 | 50.00% 10-Q · filed 2021-05-17 | |
| 2021-03-25 | 50.00% 10-K · filed 2023-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |